Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Mereo BioPharma Group plc (MREO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.1500-0.0200 (-0.92%)
At close: 4:00PM EDT
2.2000 +0.05 (+2.33%)
After hours: 07:59PM EDT
Advertisement

Mereo BioPharma Group plc

1 Cavendish Place
4th Floor
London W1G 0QF
United Kingdom
44 33 3023 7300
http://www.mereobiopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees38

Key Executives

NameTitlePayExercisedYear Born
Dr. Denise Scots-Knight Ph.D.Co-Founder, CEO & Exec. Director1.2MN/A1959
Mr. Charles SermonCo-Founder, Gen. Counsel & Company Sec.877.59kN/A1969
Dr. Alastair MacKinnon M.D., MBBSCo-Founder and Chief of Portfolio & Pipeline Strategy864.78kN/A1970
Dr. John P. Richard M.B.A., MBACo-Founder & Chief Bus. Officer819.72kN/A1957
Dr. John A. Lewicki Ph.D.Chief Scientific Officer775.16kN/A1952
Ms. Alexandra Hughes-WilsonChief of Patient Access & Commercial Planning496.63kN/A1971
Ms. Christine Fox CPAChief Financial OfficerN/AN/A1981
Dr. Fiona BorHead of Intellectual PropertyN/AN/AN/A
Dr. Jackie ParkinTherapy Area Head of Respiratory EndocrinologyN/AN/AN/A
Dr. Arun MistryTherapeutic Area Head of SetrusumabN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.

Corporate Governance

Mereo BioPharma Group plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement